Glaritus 100 Iu/ml Injection 3 ml

• Diabetes

Side effects are undesirable symptoms that can result from any medical treatment. Like any other medicine, Glaritus 100 Iu/ml Injection 3 ml   also causes some adverse impact on the body, most of which resolve without any medical attention.
Some common side effects include:

• Edema (swelling)
• Allergic reaction
• Injection site reactions (pain, swelling, redness)
• Rash
• Lipodystrophy (skin thickening or pits at the injection site)
• Itching
• Weight gain
• Hypoglycemia (low blood glucose level)

Seek medical attention in case of any unusual or severe side effects immediately.

• Dosage of the Glaritus 100 Iu/ml Injection 3 ml decide according to the type of diabetes and overall health condition of the patient. This injection can be administered by a doctor or nurse or your care giver may be taught on how to use this medicine at home.
• In case of an overdose, the doctor will provide emergency medical treatment. Do not stop or change the dose without informing your doctor.
  
  

• Glaritus 100IU/ml Injection 3ml is a prescription based long-acting type of insulin. It helps to treat type 1 & type 2 diabetes by providing consistent and all-day sugar control.
• It works like the body's natural insulin. Insulin facilitates the reuptake of sugar in muscle and fat cells as well as suppresses sugar production in the liver.
  
  

• Dunn, C. J., Plosker, G. L., Keating, G. M., McKeage, K., & Scott, L. J. (2003). Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs, 63(16), 1743-1778. https://pubmed.ncbi.nlm.nih.gov/12904090/
• Upadhayay, D. K., Palaian, S., Prabhu, M., Shankar, P. R., & Mishra, P. (2008). Insulin glargine. Journal of Institute of Medicine Nepal, 30(1), 72-77. https://www.nepjol.info/index.php/JIOM/article/view/1385
• Vrebalov Cindro, P., Krnić, M., Modun, D., Vuković, J., Tičinović Kurir, T., Kardum, G. ... & Bukić, J. (2022). Comparison of the impact of insulin degludec U100 and insulin glargine U300 on glycemic variability and oxidative stress in insulin-naive patients with type 2 diabetes mellitus: Pilot study for a randomized trial. JMIR formative research, 6(7), e35655. https://pubmed.ncbi.nlm.nih.gov/35802405/
• Heise, T., Hoevelmann, U., Nosek, L., Hermanski, L., Bøttcher, S. G., & Haahr, H. (2015). Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert opinion on drug metabolism & toxicology, 11(8), 1193-1201. https://pubmed.ncbi.nlm.nih.gov/26086190/
• Rosenstock, J., Schwartz, S. L., Clark Jr, C. M., Park, G. D., Donley, D. W., & Edwards, M. B. (2001). Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes care, 24(4), 631-636. https://pubmed.ncbi.nlm.nih.gov/11315821/